Date: 2017-12-26
Type of information: Collaboration agreement
Compound: companion diagnostic
Company: HTG Molecular Diagnostics (USA - AZ) Merck KGaA (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: companion diagnostic
Disease:
Details:
- • On October 11, 2016, HTG Molecular Diagnostics and Merck KGaA have entered a broad companion diagnostics master agreement. The initial development program agreement utilizes the HTG EdgeSeq DLBCL Cell of Origin Assay in the Merck KGaA, Darmstadt, Germany, M7583, selective and irreversible inhibitor of Burton’s Tyrosine Kinase (BTK), program.
Financial terms:
Latest news:
- • On December 26, 2017, HTG Molecular Diagnostics announced a new master collaboration agreement for translational programs with Merck KGaA. This agreement complements the previously announced master companion diagnostic Agreement with Merck KGaA and includes a statement of work with EMD Serono, the biopharmaceutical business of Merck KGaA in the United States and Canada. Under the first program statement of work, HTG plans to develop and manufacture a custom profiling assay to support biomarker research for six indications within Merck KGaA, Darmstadt, Germany’s drug development pipeline. The assay is expected to be kitted for use on HTG EdgeSeq instruments acquired by Merck KGaA and/or their contract research organization partners.
Is general: Yes
